


# BAPTA-AM

货号: **AYB26665**



## 产品信息

生物活性	BAPTA-AM is a well-known membrane permeable <b>Ca<sup>2+</sup> chelator</b> . BAPTA-AM inhibits <b>hERG</b> channels, <b>hKv1.3</b> and <b>hKv1.5</b> channels in HEK 293 cells with <b>IC<sub>50</sub>s</b> of 1.3 μM, 1.45 μM and 1.23 μM, respectively.
CAS	126150-97-8
中文名称	
分子量	764.68
体外研究	<p>BAPTA-AM inhibits neuronal Ca<sup>2+</sup>-activated K<sup>+</sup> channel currents, and up-regulates the decreased cardiac sodium current (I<sub>Na</sub>) density by chelating intracellular Ca<sup>2+</sup>.</p> <p>BAPTA-AM (BAPTA/AM), an intracellular calcium chelator, induces delayed necrosis by lipoxygenase-mediated free radicals in mouse cortical cultures. BAPTA-AM prevents free radical-mediated toxicity promote a poptosis in non-neuronal cells and produce a beneficial effect in neuronal cells by protecting neurons from ischemic damage. In addition, it has been suggested that BAPTA-AM induces a late, but not early, increase of intracellular calcium in I-IL-60 neoplastic cells. Mixed cortical cell cultures (DIV 13-16) exposed to 10 μM BAPTA-AM for 24- or 48-hr show moderate (45-70%) neuronal injury as evaluated by increased LDH release into the bathing medium after 24-48-hr. Exposure of cortical cultures to 3-10 μM BAPTA-AM for 48-hr evoke dose-dependent neuronal damage.</p> <p><b>The accuracy of these methods have not been independently confirmed. They are for reference only.</b></p>
体内研究	
形式	Solid
运输条件	Room temperature in continental US; may vary elsewhere.
保存条件	

溶解性	<p>In Vitro:  <b>DMSO : 50 mg/mL (65.39 mM; Need ultrasonic)</b>  <b>H<sub>2</sub>O : (insoluble)</b></p> <p>配制储备液</p> <table border="1"> <thead> <tr> <th>浓度</th> <th>溶剂</th> <th>体积</th> <th>质量</th> </tr> </thead> <tbody> <tr> <td>1 mg</td> <td></td> <td></td> <td></td> </tr> <tr> <td>1 mM</td> <td>1.3077 mL</td> <td>6.5387 mL</td> <td>13.0774 mL</td> </tr> <tr> <td>5 mM</td> <td>0.2615 mL</td> <td>1.3077 mL</td> <td>2.6155 mL</td> </tr> <tr> <td>10 mM</td> <td>0.1308 mL</td> <td>0.6539 mL</td> <td>1.3077 mL</td> </tr> </tbody> </table> <p>*</p> <p>请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。</p> <p>储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。</p> <p>In Vivo:  请根据您的<a href="#">实验动物和给药方式</a>选择适当的溶解方案。以下溶解方案都请先按照 <b>In Vitro</b> 方式配制澄清的储备液，再依次添加助溶剂：</p> <p>——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶</p> <ul style="list-style-type: none"> <li>1. <p>请依序添加每种溶剂： 10% DMSO 40% <a href="#">PEG300</a> 5% <a href="#">Tween-80</a> 45% saline</p> <p>Solubility: ≥ 2.5 mg/mL (3.27 mM); Clear solution</p> <p>此方案可获得 ≥ 2.5 mg/mL (3.27 mM, 饱和度未知) 的澄清溶液。</p> <p>以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入 50 μL Tween-80，混合均匀；然后继续加入 450 μL 生理盐水定容至 1 mL。</p> <p>将 0.9 g 氯化钠，完全溶解于 100 mL ddH<sub>2</sub>O 中，得到澄清透明的生理盐水溶液</p> </li> <li>2. <p>请依序添加每种溶剂： 10% DMSO 90% (20% <a href="#">SBE-β-CD</a> in saline)</p> <p>Solubility: 2.5 mg/mL (3.27 mM); Suspended solution; Need ultrasonic</p> <p>此方案可获得 2.5 mg/mL (3.27 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。</p> <p>以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。</p> <p>将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明</p> </li> <li>3. <p>请依序添加每种溶剂： 10% DMSO 90% <a href="#">corn oil</a></p> <p>Solubility: ≥ 2.5 mg/mL (3.27 mM); Clear solution</p> <p>此方案可获得 ≥ 2.5 mg/mL (3.27 mM, 饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。</p> <p>以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 玉米油中，混合均匀。</p> </li> </ul> <p>*以上所有助溶剂都可在 <a href="#">MCE</a> 网站选购。</p>	浓度	溶剂	体积	质量	1 mg				1 mM	1.3077 mL	6.5387 mL	13.0774 mL	5 mM	0.2615 mL	1.3077 mL	2.6155 mL	10 mM	0.1308 mL	0.6539 mL	1.3077 mL
浓度	溶剂	体积	质量																		
1 mg																					
1 mM	1.3077 mL	6.5387 mL	13.0774 mL																		
5 mM	0.2615 mL	1.3077 mL	2.6155 mL																		
10 mM	0.1308 mL	0.6539 mL	1.3077 mL																		
纯度	99.62%																				